Floatz logo

Recombinant respiratory syncytial virus pre-fusion F protein antigen

Lymphoma

National Heart, Lung, and Blood Institute (NHLBI)vaccinePhase 4 / ApprovedActive
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
65/ 100

Competitive context

288 Active assets in the Lymphoma cohort.

Asset / SponsorPhaseRating
VINBLASTINE
Intensity Therapeutics, Inc.
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
The Lymphoma Academic Research Organisation
Phase 4BBB
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
BLEOMYCIN
Shandong Provincial Hospital
Phase 4BB
Ifosfamide
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 3BB

View all 50 →

Same molecule, other indications

Recombinant respiratory syncytial virus pre-fusion F protein antigen is also rated in:

respiratory syncytial virus infectious diseaseDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →